%0 Journal Article
%T Resistant to Targeted Therapy - Aim for Metabolic Liabilities
%A Andr¨¦ Lima Queiroz
%A Erik Norberg
%A Helin Vakifahmetoglu-Norberg
%J Theranostics
%D 2018
%I Ivyspring International Publisher
%R 10.7150/thno.24454
%X The advent of targeted therapies generated much optimism when discovered. Targeted therapies, are however associated with rapid acquisition of resistance. In a recent study by Dong et al. (Theranostics 2018; 8(7):1808-1823. doi:10.7150/thno.23177) it was shown that lung tumors resistant to the EGFR-inhibitor (Erlotinib), reprogram their metabolism and acquire a pro-survival dependency on Phosphoglycerate Dehydrogenase (PHGDH) that can be targeted to eliminate resistant tumors.
%K EGFR
%K Lung Cancer
%K Non-small Cell Lung Carcinomas
%K Lung Adenocarcinomas
%K PHGDH
%K Tumor Metabolism
%K Serine
%U http://www.thno.org/v08p2061.htm